Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Accumulated Expenses (2024 - 2025)

Xilio Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $9.0 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 59580.0% year-over-year to $9.0 million; the TTM value through Sep 2025 reached $9.0 million, up 59580.0%, while the annual FY2024 figure was $10.0 million, N/A changed from the prior year.
  • Accumulated Expenses for Q3 2025 was $9.0 million at Xilio Therapeutics, up from $5.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.0 million in Q4 2024 and bottomed at $15000.0 in Q3 2024.